医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ITM and CIRC Sign Technology License Agreement for the Production and Distribution of Medical Radioisotopes in China

2019年11月18日 PM05:39
このエントリーをはてなブックマークに追加


 

MUNICH & GARCHING, Germany

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and Chengdu Gaotong Isotope Co., Ltd. a subsidiary of China Isotope & Radiation Corporation (CIRC), a nuclear technology application products manufacturer and supplier, announced today that they have signed a technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added (n.c.a) Lutetium-177 (EndolucinBeta®) in China.

ITM and CIRC have already been working together in a successful partnership for almost 10 years in which CIRC has distributed ITM‘s medical radioisotopes, generators and equipment to the Chinese market. China’s radiopharmaceutical market is now growing rapidly in line with the fast expanding clinical evidence and use of Targeted Radionuclide Therapies worldwide.

In order to meet the rising demand for Targeted Radionuclide Therapy in China, ITM and CIRC have decided to enter into a technology license agreement. Under the terms of the agreement, CIRC’s subsidiary Gaotong will implement the production of 68Ge/68Ga Generators and n.c.a. Lutetium-177 (EndolucinBeta®), in China for the Chinese market, as well as joining ITM’s global network of OEM suppliers in support of ITM’s international framework agreements with strategic partners. Additional terms of the agreement are not disclosed.

The global ITM OEM Network serves the worldwide radiopharmaceutical market with OEM partners in the US, Australia and South Africa providing security of supply and scalability of medical radioisotopes for the exponentially growing use of Theranostics in Precision Oncology. With this new partnership, CIRC is now the fourth partner to join the global ITM OEM Processing and Production Network.

“ITM has developed a strong presence in the Chinese market through CIRC as our distribution partner, supplying 68Ge/68Ga Generators and no-carrier-added Lutetium-177 since 2010”, said Steffen Schuster, CEO of ITM. “Now we are excited to take our established partnership to the next level. This agreement with CIRC allows us to share our manufacturing expertise in producing high-quality theranostic radioisotopes with a reliable partner who is able to implement and set highest quality standards in China. This gives us the opportunity to provide locally manufactured radioisotopes for Chinese cancer patients and also for cancer patients worldwide via our OEM Network. Through this expanded relationship with CIRC and Gaotong, we are looking forward to making Targeted Radionuclide Therapy available to a growing number of cancer patients and to jointly improving patients’ outcomes and quality of life.”

Mr. Wu Jian, General Manager of CIRC added: “We can look back on a long-standing and reliable relationship with ITM through which we have been able to offer the best next generation medical isotope products available to the emerging Chinese radiopharmaceutical market from the very beginning. With this important agreement we are taking the next step in serving Chinese cancer patients through China’s nuclear medicine practitioners in a better and timely manner and deepening our relationship with ITM at the same time. We believe that on the basis of our decades of experiences in radionuclides and radiopharmaceutical research and production, by manufacturing radioisotopes according to the unique methodologies developed by ITM and internationally accepted quality standards, particularly the theranostic pair Gallium-68 and the unrivaled no-carrier-added Lutetium-177, we will be able to supply high quality products to help many cancer patients in China and provide an economically sustainable solution for the Chinese Health Care System.“

– Ends –

ITM Isotopen Technologien München AG
Chairman of the Supervisory Board – Udo J. Vetter, Executive Board – Steffen Schuster (Chairman), Thomas Dürre
Registered Office of the Company – Lichtenbergstrasse 1, 85748 Garching bei München – Commercial Register Munich – HRB 15494

View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005319/en/

CONTACT

ITM Contact

Nicola Scharrer

Head of Marketing

Phone: +49 89 329 89 86 151

Email: Nicola.Scharrer@itm.ag

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 内布拉斯加大学医学中心和阿南达宣布,FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验
  • Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
  • Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods
  • MSITEK Sponsors a Hospice IT and Digital Project in India as Part of CSR (Corporate Social Responsibility) Initiatives
  • XlearがDr. Ferrer BioPharmaと提携し、以前にも増して優れたユーザー体験を鼻腔衛生にもたらす